Lipella Pharmaceuticals (LIPO) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for September 10, 2024, to be held virtually, with voting on key proposals including director elections, a reverse stock split, and auditor ratification.

• Record date for voting eligibility is August 1, 2024, with 7,605,636 shares of common stock outstanding.

• Board recommends voting in favor of all proposals and director nominees.

Voting matters and shareholder proposals

• Proposals include electing seven directors, authorizing a reverse stock split (ratio 1-for-5 to 1-for-150), and ratifying Urish Popeck & Co., LLC as independent auditors for 2024.

• Reverse stock split aims to maintain Nasdaq listing by addressing minimum bid price requirements.

• Shareholders may submit future proposals for the 2025 meeting between May 13 and June 12, 2025.

Board of directors and corporate governance

• Board consists of seven members, majority independent per Nasdaq rules.

• Committees include audit, compensation, and nominating/governance, all with independent members.

• Board diversity matrix and attendance at meetings disclosed; no family relationships among directors.

• CEO also serves as Chairman; no lead independent director.